Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.

Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.

Abstract: The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of ischemic stroke comprising administering an aptamer of the present disclosure to a subject in need thereof, alone or combination with other pharmacological and/or surgical interventions. In a particular aspect, the aptamers of the present disclosure are administered before, during, of after thrombolysis (e.g., thrombectomy) or any combination thereof. The disclosure also provides specific doses and dosage regimes.

Abstract: The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of a TLR-4 mediated disease or condition comprising administering an aptamer of the present disclosure to a subject in need thereof, alone or combination with other pharmacological and/or surgical interventions. In a particular aspect, the aptamers of the present disclosure are administered before, during, or after pharmacological and/or surgical interventions (e.g., thrombolysis such as thrombectomy) or any combination thereof, for the treatment of ischemic (e.g., myocardial infarction or ischemic stroke), hemorrhagic (e.g., hemorrhagic stroke or hemorrhagic transformation), or neurodegenerative (e.g., multiple sclerosis) diseases or conditions. The disclosure also provides specific doses and dosage regimes.

Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.

Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.

Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.

Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.